DIO TREE

Company Overview

Snapshot

Founded in October 2022 by Osnat Ashur-Fabian, DIO TREE operates with 1–10 employees. The company has raised $1.05 million across two funding rounds from two investors. In January 2024, DIO TREE secured a grant from the Israel Innovation Authority.

Business overview

DIO TREE is a Health Tech & Life Sciences company focused on developing a novel small molecule for the treatment of ovarian cancer. Its core technology targets the enzyme DIO3, identified as a significant driver in various cancer types, particularly ovarian cancer. The company's product pipeline consists of a series of small molecules designed to inhibit DIO3, serving the healthcare and biotechnology sectors by addressing patient needs in oncology.

Strategic signal

In August 2023, DIO TREE was featured in a CTech article highlighting its potential to significantly impact cancer treatment with a single drug. This underscores the company's innovative approach in the oncology space and signals strong validation of its therapeutic strategy for investors and innovation teams.

Company Intelligence Q&A

What is DIO TREE's primary focus?

DIO TREE is developing a novel small molecule for the treatment of ovarian cancer, targeting the DIO3 enzyme which is a major driver in many cancer types.

When was DIO TREE founded?

DIO TREE was founded in October 2022.

Who is a key founder of DIO TREE?

Osnat Ashur-Fabian is a founder and the CSO of DIO TREE.

Which investor participated in DIO TREE's December 2022 funding round?

In December 2022, DIO TREE received funding from NGT HealthCare II and the Israel Innovation Authority.